Abe M - Search Results

1

TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.

Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T, Nakamura S, Ashtar M, Shimizu S, Iwasa M, Sogabe K, Oura M, Fujii S, Kagawa K, Miki H, Endo I, Haneji T, Matsumoto T, Abe M. Teramachi J, et al. Among authors: abe m. Haematologica. 2021 May 1;106(5):1401-1413. doi: 10.3324/haematol.2019.234476. Haematologica. 2021. PMID: 32273474 Free PMC article.

2

[Effect of bisphosphonate on myeloma bone disease].

Abe M, Matsumoto T, Kosaka M. Abe M, et al. Rinsho Ketsueki. 2002 May;43(5):349-52. Rinsho Ketsueki. 2002. PMID: 12096484 Japanese. No abstract available.

3

Potent induction of activin A secretion from monocytes and bone marrow stromal fibroblasts by cognate interaction with activated T cells.

Abe M, Shintani Y, Eto Y, Harada K, Kosaka M, Matsumoto T. Abe M, et al. J Leukoc Biol. 2002 Aug;72(2):347-52. J Leukoc Biol. 2002. PMID: 12149426

4

Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.

Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T. Abe M, et al. Blood. 2002 Sep 15;100(6):2195-202. Blood. 2002. PMID: 12200385 Free article.

5

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.

Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Hashimoto T, et al. Among authors: abe m. Br J Haematol. 2004 Apr;125(1):38-41. doi: 10.1111/j.1365-2141.2004.04864.x. Br J Haematol. 2004. PMID: 15015966 Free article.

6

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Abe M, et al. Blood. 2004 Oct 15;104(8):2484-91. doi: 10.1182/blood-2003-11-3839. Epub 2004 Jun 8. Blood. 2004. PMID: 15187021 Free article.

7

[Biochemical markers in bone metastasis].

Hashimoto T, Abe M, Matsumoto T. Hashimoto T, et al. Among authors: abe m. Gan To Kagaku Ryoho. 2004 Jul;31(7):1027-33. Gan To Kagaku Ryoho. 2004. PMID: 15272580 Review. Japanese.

8

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T. Oshima T, et al. Among authors: abe m. Blood. 2005 Nov 1;106(9):3160-5. doi: 10.1182/blood-2004-12-4940. Epub 2005 Jul 19. Blood. 2005. PMID: 16030194 Free article.

9

Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.

Jalili A, Ozaki S, Hara T, Shibata H, Hashimoto T, Abe M, Nishioka Y, Matsumoto T. Jalili A, et al. Among authors: abe m. Blood. 2005 Nov 15;106(10):3538-45. doi: 10.1182/blood-2005-04-1438. Epub 2005 Jul 21. Blood. 2005. PMID: 16037388 Free article.

10

Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.

Shibata H, Abe M, Hiura K, Wilde J, Moriyama K, Sano T, Kitazoe K, Hashimoto T, Ozaki S, Wakatsuki S, Kido S, Inoue D, Matsumoto T. Shibata H, et al. Among authors: abe m. Clin Cancer Res. 2005 Sep 1;11(17):6109-15. doi: 10.1158/1078-0432.CCR-05-0181. Clin Cancer Res. 2005. PMID: 16144909

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,178 results

Search Page